Observational studyJournal of atherosclerosis and thrombosis2023

Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan.

Po-Lin Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.